筹划控制权变更并拟购北京金康普股权，莱茵生物12月10日起停牌

Core Viewpoint - Rhine Biotech (002166) announced a suspension of its stock trading starting December 10 due to plans for a change in control, issuance of shares, and cash payment for asset acquisition, with the suspension expected to last no more than 10 trading days [1] Group 1: Control Change - The controlling shareholder and actual controller, Qin Benjun, is planning to transfer part of his shares and relinquish voting rights [1] - A "Control Change Intent Agreement" has been signed with the counterparty, Guangzhou Defu Nutrition Investment Partnership (Limited Partnership) [1] Group 2: Acquisition Details - Rhine Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment [1] - Following the transaction, Beijing Jinkangpu will become a subsidiary of Rhine Biotech and will be included in the consolidated financial statements [1] - The transaction is not classified as a major asset restructuring or restructuring listing, but it is expected to constitute a related party transaction [1] Group 3: Company Background - Beijing Jinkangpu, established in 2004, specializes in the compounding, testing, sales, and technical development of food nutrition fortifiers [1] - Rhine Biotech's core products include natural sweeteners [1]